Pharmaceutical

Editas trades part of Vertex CRISPR therapy licencing rights deal for $57m

Oct 6, 2024 - 04:00
Editas trades part of Vertex CRISPR therapy licencing rights deal for $57m

Read the original article

Tags:

Previous Article

Can You Lose Weight With Vitamin B12?

Next Article

WuXi debates sale of pharma operations as BIOSECURE Act advances

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Hot antitrust environment hangs over called-off merger between Cigna and Humana

STAT+: Hot antitrust environment hangs over called-off ...

Dec 11, 2023

Gebasaxturev by Merck for Oral Cavity (Mouth) Cancer: Likelihood of Approval

Gebasaxturev by Merck for Oral Cavity (Mouth) Cancer: L...

Nov 2, 2023

M&A in pharmaceutical in Canada increased in Q2 2023

Jul 27, 2023